Lantheus Holdings, Inc. (LNTH)
LNTH Stock Price Chart
Explore Lantheus Holdings, Inc. interactive price chart. Choose custom timeframes to analyze LNTH price movements and trends.
LNTH Company Profile
Discover essential business fundamentals and corporate details for Lantheus Holdings, Inc. (LNTH) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
25 Jun 2015
Employees
808.00
Website
https://www.lantheus.comCEO
Mary Anne Heino
Description
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.
LNTH Financial Timeline
Browse a chronological timeline of Lantheus Holdings, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is $1.33, while revenue estimate is $362.99m.
Earnings released on 7 May 2026
EPS came in at $1.46 surpassing the estimated $1.25 by +16.80%, while revenue for the quarter reached $377.33m , beating expectations by +6.45%.
Earnings released on 26 Feb 2026
EPS came in at $1.67 surpassing the estimated $1.18 by +41.53%, while revenue for the quarter reached $406.79m , beating expectations by +10.84%.
Earnings released on 6 Nov 2025
EPS came in at $1.27 matching the estimated $1.27, while revenue for the quarter reached $384.01m , beating expectations by +4.36%.
Earnings released on 6 Aug 2025
EPS came in at $1.57 falling short of the estimated $1.64 by -4.27%, while revenue for the quarter reached $378.05m , beating expectations by +4.05%.
Earnings released on 7 May 2025
EPS came in at $1.53 falling short of the estimated $1.68 by -8.93%, while revenue for the quarter reached $372.76m , missing expectations by -5.69%.
Earnings released on 26 Feb 2025
EPS came in at $1.59 surpassing the estimated $1.58 by +0.63%, while revenue for the quarter reached $391.11m , beating expectations by +3.07%.
Earnings released on 6 Nov 2024
EPS came in at $1.70 surpassing the estimated $1.56 by +8.97%, while revenue for the quarter reached $378.73m , beating expectations by +0.77%.
Earnings released on 31 Jul 2024
EPS came in at $1.80 falling short of the estimated $1.83 by -1.64%, while revenue for the quarter reached $394.09m , beating expectations by +3.12%.
Earnings released on 2 May 2024
EPS came in at $1.69 surpassing the estimated $1.54 by +9.74%, while revenue for the quarter reached $369.98m , missing expectations by -3.19%.
Earnings released on 22 Feb 2024
EPS came in at $1.75 surpassing the estimated $1.45 by +20.69%, while revenue for the quarter reached $354.00m , beating expectations by +3.41%.
Earnings released on 2 Nov 2023
EPS came in at $1.47 surpassing the estimated $1.32 by +11.36%, while revenue for the quarter reached $319.95m , beating expectations by +1.80%.
Earnings released on 3 Aug 2023
EPS came in at $1.54 surpassing the estimated $1.31 by +17.56%, while revenue for the quarter reached $321.70m , beating expectations by +5.22%.
Earnings released on 4 May 2023
EPS came in at $1.47 surpassing the estimated $1.29 by +13.95%, while revenue for the quarter reached $300.78m , beating expectations by +7.18%.
Earnings released on 23 Feb 2023
EPS came in at $1.37 surpassing the estimated $0.96 by +42.71%, while revenue for the quarter reached $263.17m , beating expectations by +7.53%.
Earnings released on 3 Nov 2022
EPS came in at $0.99 surpassing the estimated $0.83 by +19.28%, while revenue for the quarter reached $239.29m , beating expectations by +4.95%.
Earnings released on 4 Aug 2022
EPS came in at $0.89 surpassing the estimated $0.70 by +27.14%, while revenue for the quarter reached $223.72m , beating expectations by +9.45%.
Earnings released on 29 Apr 2022
EPS came in at $0.97 surpassing the estimated $0.46 by +110.87%, while revenue for the quarter reached $208.88m , beating expectations by +26.36%.
Earnings released on 24 Feb 2022
EPS came in at $0.25 surpassing the estimated $0.17 by +47.06%, while revenue for the quarter reached $129.56m , beating expectations by +15.91%.
Earnings released on 4 Nov 2021
EPS came in at $0.08 surpassing the estimated $0.06 by +33.33%, while revenue for the quarter reached $102.07m , beating expectations by +5.09%.
Earnings released on 28 Jul 2021
EPS came in at $0.11 surpassing the estimated $0.05 by +120.00%, while revenue for the quarter reached $101.06m , beating expectations by +34.68%.
LNTH Stock Performance
Access detailed LNTH performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
